News Center

Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer

3月 17, 2021 | 未分类
SAN DIEGO, Calif., March 17, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced that the U.S. Food and...

Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

2月 23, 2021 | 未分类
SAN DIEGO, Calif., February 23, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet...

FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer

1月 4, 2021 | 未分类
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or...

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

12月 10, 2020 | 未分类
• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU • Multiple Global Phase...

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics

11月 9, 2020 | 未分类
SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed...